drugset / Trial / NCT02648516

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients

NCT02648516 ↗

Phase 1/2 Unknown 20 enrolled Beijing 302 Hospital
NaSingle-groupOpen-labelTreatment

Summary

Combination antiretroviral therapy (ART) effectively suppresses viral replication, leading to a significant immune recovery and a dramatic reduction in the incidence of AIDS-defining events. However, approximately 20% of individuals who exhibit stable viral suppression by ART, but fail to achieve sufficient immune reconstitution and are considered immune nonresponders (INRs). These INRs often experience an increased risk of opportunistic infections and shorter life expectancy compared with matched immune responders.Therefore, efficiently treating these immune nonresponders has become one of the most difficult challenges in the clinic.

Timeline

Start
2016-10
Primary completion
2021-07
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject allogeneic adoptive immune therapy Cell therapy 2e+08 cells/kg Intravenous
Subject allogeneic adoptive immune therapy Cell therapy 3e+08 cells/kg Intravenous